← 產業報告目錄

Radiotherapy Market by Technology (EBRT: LINAC, Stereotactic, Particle; Internal Beam/Brachytherapy, Cobalt-60 Teletherapy), Procedure (IGRT, IMRT, 3D-CRT, LDR, PDR), Cancer (Prostate, Lung, Breast, CRC), End User (Hospital, IRC) - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-06-03頁數 328報告編號 MD1773

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global radiotherapy market is expected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, registering a CAGR of 6.0% during the forecast period. The advancements in radiotherapy technology are expected to significantly boost market growth in the coming years. However, the high costs of radiotherapy products may hinder market expansion. “The external beam radiotherapy segment held the largest share of the market in 2025.” By technology, the radiotherapy market is categorized into external beam radiotherapy and internal beam radiotherapy/brachytherapy. During the forecast period, the external beam radiotherapy segment is expected to hold the largest market share. This is due to its ability to accurately target tumors while minimizing exposure to surrounding healthy tissue. The growth of this segment is driven by the increasing adoption of advanced procedures and a rising demand for precision medicine. “The external beam radiotherapy procedures segment is expected to hold the largest share of the market in 2025.” By procedure, the radiotherapy market can be categorized into external beam radiotherapy and internal beam radiotherapy/brachytherapy procedures. The external beam radiotherapy procedures segment is expected to dominate the market during the forecast period. This is due to their accuracy, which allows for precise targeting of tumors while minimizing radiation exposure to healthy tissues. Additionally, external beam radiotherapy is commonly used to treat cancer. Innovations in image-guided and intensity-modulated radiotherapy systems are further driving the growth of this segment. “The hospital segment is expected to hold the largest share of the market in 2025.” By end user, the radiotherapy market is categorized into hospitals and standalone radiotherapy centers. In the coming years, the hospitals segment is expected to capture the largest share of the global radiotherapy market. This growth can be attributed to several factors, including a high patient volume, the availability of advanced radiotherapy equipment, and the increasing demand for comprehensive cancer treatment facilities within hospitals. Additionally, the expansion of hospitals in developing countries, investments in healthcare infrastructure, and the availability of trained oncologists will further support the growth of this segment. “The market in the APAC region is expected to register the highest growth rate during the forecast period.” The radiotherapy market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America plays a significant role in the global radiotherapy market due to its established healthcare infrastructure, advanced radiotherapy equipment, favorable reimbursement policies, and the presence of key market players. However, the Asia Pacific region is expected to experience the highest growth rate during the forecast period. This growth is driven by the rising incidence of cancer, increased investment in healthcare, enhanced funding for oncology treatments, and advancements in healthcare infrastructure in countries such as China, India, and Japan, all of which have led to greater adoption of radiotherapy. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: Directors (18%), C-level Executives (27%), and Other Designations (55%) • By Region: North America (50%), Europe (20%), Asia Pacific (10%), Latin America (10%), and the Middle East & Africa (10%) The prominent players in the radiotherapy market are Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Sumitomo Heavy Industries Ltd. (Japan), Carl Zeiss Meditec AG (Germany), and Koninklijke Philips N.V. (Netherlands), among others. Research Coverage This report studies the radiotherapy market based on offering, technology, application, procedure, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions). Reasons to Buy the Report The report will enable established firms, as well as entrants/smaller firms, to gauge the pulse of the market, which, in turn, will help them garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence. This report provides insights into the following pointers: • Analysis of key drivers (advancements in radiotherapy treatment technology, growing patient population, increasing initiatives to promote radiotherapy awareness, and growing use of particle therapy for cancer treatment), restraints (high cost of advanced lab consumables and environmental sustainability concerns), opportunities (lack of adequate healthcare infrastructure, high capital cost of radiotherapy, and complexity of radiotherapy), and challenges (dearth of skilled personnel, difficulties in visualizing tumors during radiotherapy, and risk of Radiation Exposure) influencing the growth of the radiotherapy market. • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the radiotherapy market. • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product developments in the radiotherapy market. • Market Development: Comprehensive information on lucrative emerging regions. • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the radiotherapy market. • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
目錄 Table of Contents
1 INTRODUCTION 29 1.1 STUDY OBJECTIVES 29 1.2 MARKET DEFINITION 29 1.3 MARKET SCOPE 30 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 30 1.3.2 INCLUSIONS & EXCLUSIONS 31 1.3.3 YEARS CONSIDERED 32 1.3.4 CURRENCY CONSIDERED 32 1.4 STAKEHOLDERS 32 1.5 SUMMARY OF CHANGES 33 2 EXECUTIVE SUMMARY 34 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 34 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 35 2.3 DISRUPTIVE TRENDS IN RADIOTHERAPY MARKET 36 2.4 HIGH-GROWTH SEGMENTS 37 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 38 3 PREMIUM INSIGHTS 39 3.1 RADIOTHERAPY MARKET OVERVIEW 39 3.2 RADIOTHERAPY MARKET, BY REGION 40 3.3 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY AND COUNTRY 40 3.4 GEOGRAPHIC SNAPSHOT OF RADIOTHERAPY MARKET 41 4 MARKET OVERVIEW 42 4.1 INTRODUCTION 42 4.2 MARKET DYNAMICS 42 4.2.1 DRIVERS 43 4.2.1.1 Advancements in radiotherapy treatment 43 4.2.1.2 AI and automation in treatment planning 45 4.2.1.3 Increasing government investments and awareness initiatives for cancer care 46 4.2.2 RESTRAINTS 46 4.2.2.1 High costs associated with radiotherapy systems such as proton therapy and advanced linear accelerators 46 4.2.2.2 Limited access to advanced radiotherapy infrastructure and skilled workforce in low- and middle-income countries 47 4.2.2.3 Shortage of skilled radiation oncologists, medical physicists, and trained technicians 47   4.2.3 OPPORTUNITIES 47 4.2.3.1 Emerging markets offer significant growth potential for radiotherapy technologies 47 4.2.3.2 Integration of radiotherapy with immunotherapy and systemic therapies 48 4.2.3.3 Growing adoption of outpatient radiotherapy and hypofractionated treatment regimens 49 4.2.4 CHALLENGES 50 4.2.4.1 Increasing cybersecurity and data protection challenges in digital radiotherapy ecosystems 50 4.2.4.2 Patient safety concerns and radiation exposure risks 50 4.3 UNMET NEEDS 51 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52 5 INDUSTRY TRENDS 54 5.1 PORTER’S FIVE FORCES ANALYSIS 54 5.1.1 INTENSITY OF COMPETITIVE RIVALRY 55 5.1.2 BARGAINING POWER OF SUPPLIERS 55 5.1.3 BARGAINING POWER OF BUYERS 56 5.1.4 THREAT OF SUBSTITUTES 56 5.1.5 THREAT OF NEW ENTRANTS 56 5.2 MACROECONOMIC OUTLOOK 56 5.2.1 GDP TRENDS AND FORECAST 56 5.2.2 TRENDS IN GLOBAL RADIOTHERAPY INDUSTRY 57 5.3 VALUE CHAIN ANALYSIS 57 5.3.1 RESEARCH & DEVELOPMENT 58 5.3.2 PROCUREMENT & MANUFACTURING 58 5.3.3 MARKETING, SALES, AND DISTRIBUTION 58 5.4 ECOSYSTEM ANALYSIS 59 5.5 PRICING ANALYSIS 59 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION 60 5.6 TRADE ANALYSIS 62 5.6.1 IMPORT DATA (HS CODE 902214) 62 5.6.2 EXPORT DATA (HS CODE 902214) 63 5.7 KEY CONFERENCES & EVENTS, 2026–2027 64 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 64 5.9 INVESTMENT & FUNDING SCENARIO 65 5.10 CASE STUDY ANALYSIS 67 5.10.1 SBRT’S ROLE IN MINIMIZING RADIATION RISK IN ELDERLY PATIENTS 67 5.10.2 RADIOTHERAPY FOR BREAST CANCER IN PATIENTS WITH HEREDITARY COPROPORPHYRIA 67 5.10.3 RADIATION THERAPY TREATMENT FOR TRANSITIONAL CELL CARCINOMA OF DISTAL URETHRA 68   5.11 IMPACT OF 2025 US TARIFF - RADIOTHERAPY MARKET 68 5.11.1 KEY TARIFF RATES 69 5.11.2 PRICE IMPACT ANALYSIS 69 5.11.3 IMPACT ON COUNTRIES/REGIONS 70 5.11.4 IMPACT ON END-USE INDUSTRIES 71 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 72 6.1 KEY TECHNOLOGIES 72 6.1.1 MR-GUIDED ADAPTIVE RADIOTHERAPY 72 6.1.2 ARTIFICIAL INTELLIGENCE-DRIVEN TREATMENT PLANNING 72 6.1.3 PROTON AND PARTICLE THERAPY 73 6.2 COMPLEMENTARY TECHNOLOGIES 73 6.2.1 ADVANCED TREATMENT PLANNING SYSTEMS AND AI-ENABLED DECISION SUPPORT 73 6.2.2 CLOUD-BASED AND REMOTE RADIOTHERAPY PLATFORMS 74 6.3 PATENT ANALYSIS 74 6.3.1 INNOVATIONS AND PATENT REGISTRATIONS 76 6.4 FUTURE APPLICATIONS 77 6.5 IMPACT OF AI/GEN AI ON RADIOTHERAPY MARKET 77 6.5.1 TOP USE CASES AND MARKET POTENTIAL 79 6.5.2 BEST PRACTICES FOLLOWED BY MANUFACTURERS IN RADIOTHERAPY MARKET 80 6.5.3 CASE STUDIES RELATED TO AI IMPLEMENTATION IN RADIOTHERAPY MARKET 80 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS 81 6.5.5 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN RADIOTHERAPY MARKET 82 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 82 7 REGULATORY LANDSCAPE 84 7.1 REGIONAL REGULATIONS AND COMPLIANCE 84 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 7.1.2 INDUSTRY STANDARDS 86 7.1.2.1 North America 86 7.1.2.1.1 US 86 7.1.2.1.2 Canada 87 7.1.2.2 Europe 88 7.1.2.3 Asia Pacific 88 7.1.2.3.1 China 88 7.1.2.3.2 Japan 89 7.1.2.3.3 India 90   8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 91 8.1 DECISION-MAKING PROCESS 91 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 92 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 92 8.2.2 BUYING CRITERIA 92 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 93 8.4 UNMET NEEDS FROM END-USERS 94 9 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 95 9.1 INTRODUCTION 96 9.2 SYSTEMS 96 9.2.1 INCREASING ADOPTION OF AI-ENABLED AND IMAGE-GUIDED RADIOTHERAPY SYSTEMS TO DRIVE GROWTH 96 9.3 SOFTWARE & SERVICES 97 9.3.1 INCREASING ADOPTION OF INTEGRATED ONCOLOGY SOFTWARE PLATFORMS TO SUPPORT MARKET GROWTH 97 10 RADIOTHERAPY MARKET, BY APPLICATION 99 10.1 INTRODUCTION 100 10.2 EXTERNAL BEAM RADIOTHERAPY 100 10.2.1 PROSTATE CANCER 101 10.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth 101 10.2.2 BREAST CANCER 102 10.2.2.1 Therapeutic benefits of EBRT to drive market 102 10.2.3 LUNG CANCER 103 10.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market 103 10.2.4 HEAD & NECK CANCER 104 10.2.4.1 Increasing preference for noninvasive treatment of head & neck cancers to drive market 104 10.2.5 COLORECTAL CANCER 105 10.2.5.1 High incidence of colorectal cancer to support market growth 105 10.2.6 OTHER EBRT APPLICATIONS 106 10.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 107 10.3.1 PROSTATE CANCER 108 10.3.1.1 Precision of brachytherapy to drive market 108 10.3.2 GYNECOLOGICAL CANCER 109 10.3.2.1 Availability of alternatives to hinder adoption of brachytherapy 109 10.3.3 BREAST CANCER 110 10.3.3.1 Growing adoption of accelerated partial breast irradiation drives breast brachytherapy utilization 110 10.3.4 CERVICAL CANCER 111 10.3.4.1 MRI-guided adaptive brachytherapy and AI-enabled planning drive advances in cervical cancer treatment 111 10.3.5 PENILE CANCER 112 10.3.5.1 Increasing awareness of organ-preservation strategies to drive market 112 10.3.6 OTHER IBRT APPLICATIONS 113 11 RADIOTHERAPY MARKET, BY PROCEDURE 114 11.1 INTRODUCTION 115 11.2 EXTERNAL BEAM RADIOTHERAPY 115 11.2.1 IMAGE-GUIDED RADIOTHERAPY 117 11.2.1.1 Growing adoption of real-time imaging and adaptive workflows to support market growth 117 11.2.2 INTENSITY-MODULATED RADIOTHERAPY 118 11.2.2.1 Growing adoption of hypofractionation and adaptive treatment planning to propel market 118 11.2.3 PARTICLE THERAPY 119 11.2.3.1 Advancements in treatment planning systems and expansion of proton therapy facilities to drive adoption 119 11.2.4 3D CONFORMAL RADIOTHERAPY 120 11.2.4.1 Continued utilization in resource-constrained settings to support adoption of 3D-CRT 120 11.2.5 STEREOTACTIC RADIOTHERAPY 121 11.2.5.1 Expanding clinical applications and hypofractionated treatment approaches to propel adoption 121 11.2.6 OTHER EBRT PROCEDURES 122 11.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 123 11.3.1 LDR BRACHYTHERAPY 124 11.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption 124 11.3.2 HDR BRACHYTHERAPY 125 11.3.2.1 Advancements in image-guided planning and dose optimization to drive growth 125 11.3.3 PDR BRACHYTHERAPY 126 11.3.3.1 Better radiation safety, easier prospective planning, and precise dose shaping to drive adoption 126 12 RADIOTHERAPY MARKET, BY TECHNOLOGY 127 12.1 INTRODUCTION 128 12.2 EXTERNAL BEAM RADIOTHERAPY 128 12.2.1 LINACS 129 12.2.1.1 Conventional LINACs 131 12.2.1.1.1 Long treatment duration to limit adoption 131 12.2.1.2 Stereotactic advanced electron/cobalt-60 LINACs 131 12.2.1.2.1 CyberKnife 132 12.2.1.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market 132 12.2.1.2.2 Gamma Knife 134 12.2.1.2.2.1 Advancements in precision intracranial radiosurgery to drive adoption 134 12.2.1.2.3 TomoTherapy 135 12.2.1.2.3.1 Accurate targeting of tumors and minimization of exposure to surrounding healthy tissues to drive adoption 135 12.2.1.3 MRI LINACs 136 12.2.1.3.1 Real-time imaging advantage to propel growth 136 12.2.2 PARTICLE THERAPY 137 12.2.2.1 Cyclotrons 138 12.2.2.1.1 Enhanced outcomes and other advantages to boost adoption 138 12.2.2.2 Synchrotrons 139 12.2.2.2.1 Increasing investments in synchrotron facilities to drive market 139 12.2.2.3 Synchrocyclotrons 140 12.2.2.3.1 Compact synchrocyclotron innovations support adoption despite infrastructure challenges 140 12.2.3 CONVENTIONAL COBALT-60 TELETHERAPY 141 12.2.3.1 Complex dose delivery planning and radiation exposure to limit market adoption 141 12.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY 142 12.3.1 SEEDS 143 12.3.1.1 Adverse effects associated with brachytherapy seeds to limit adoption 143 12.3.2 AFTERLOADERS 144 12.3.2.1 Proper positioning and better control of isotopes in modern afterloaders to drive demand 144 12.3.3 IORT SYSTEMS 145 12.3.3.1 Growing clinical evidence supporting long-term efficacy to drive adoption 145 12.3.4 APPLICATORS 146 12.3.4.1 High risk of radiation exposure in manual applicators to limit growth 146 13 RADIOTHERAPY MARKET, BY END USER 148 13.1 INTRODUCTION 149 13.2 HOSPITALS 149 13.2.1 INCREASING ADOPTION OF AI-ENABLED AND PRECISION RADIATION THERAPY SOLUTIONS TO DRIVE MARKET 149 13.3 INDEPENDENT RADIOTHERAPY CENTERS 150 13.3.1 EXPANSION OF RADIOTHERAPY INFRASTRUCTURE AND COMMUNITY-BASED CANCER CARE TO PROPEL MARKET 150   14 RADIOTHERAPY MARKET, BY REGION 152 14.1 INTRODUCTION 153 14.2 NORTH AMERICA 153 14.2.1 US 159 14.2.1.1 Favorable reimbursement scenario to drive growth 159 14.2.2 CANADA 161 14.2.2.1 Favorable initiatives from government and private organizations to boost market 161 14.3 EUROPE 164 14.3.1 GERMANY 169 14.3.1.1 Availability of novel radiotherapy products to drive market 169 14.3.2 FRANCE 171 14.3.2.1 Presence of advanced healthcare systems to augment growth 171 14.3.3 UK 173 14.3.3.1 Growing adoption of advanced radiotherapy technologies and rising cancer burden to drive market 173 14.3.4 SPAIN 176 14.3.4.1 Adoption of advanced radiotherapy technologies to drive market 176 14.3.5 ITALY 178 14.3.5.1 Rising adoption of advanced radiotherapy technologies and strong research ecosystem to support market growth 178 14.3.6 REST OF EUROPE 180 14.4 ASIA PACIFIC 181 14.4.1 JAPAN 187 14.4.1.1 Favorable reimbursement policies to propel market 187 14.4.2 CHINA 189 14.4.2.1 Precision oncology investments to drive market 189 14.4.3 INDIA 192 14.4.3.1 Growing cancer burden, infrastructure investments, and advanced technology adoption to drive market 192 14.4.4 SOUTH KOREA 194 14.4.4.1 Rising investments in heavy-ion therapy infrastructure to propel market 194 14.4.5 AUSTRALIA 196 14.4.5.1 Growing cancer cases to fuel market 196 14.4.6 REST OF ASIA PACIFIC 198 14.5 LATIN AMERICA 199 14.5.1 BRAZIL 205 14.5.1.1 Increasing prevalence of cancer to fuel market 205 14.5.2 MEXICO 207 14.5.2.1 Expanding oncology infrastructure and precision radiotherapy adoption to drive growth 207 14.5.3 REST OF LATIN AMERICA 209 14.6 MIDDLE EAST & AFRICA 211 14.6.1 GCC COUNTRIES 216 14.6.1.1 Increasing investments in advanced oncology infrastructure to propel market 216 14.6.2 REST OF MIDDLE EAST & AFRICA 218 15 COMPETITIVE LANDSCAPE 220 15.1 INTRODUCTION 220 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 220 15.2.1 KEY PLAYER COMPETITIVE STRATEGIES IN RADIOTHERAPY MARKET, JANUARY 2022–MAY 2026 220 15.3 REVENUE ANALYSIS, 2021–2025 224 15.4 MARKET SHARE ANALYSIS, 2025 225 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 227 15.5.1 STARS 227 15.5.2 EMERGING LEADERS 227 15.5.3 PERVASIVE PLAYERS 227 15.5.4 PARTICIPANTS 227 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 229 15.5.5.1 Company footprint 229 15.5.5.2 Region footprint 230 15.5.5.3 Technology footprint 230 15.5.5.4 Application footprint 231 15.5.5.5 End-user footprint 232 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 232 15.6.1 PROGRESSIVE COMPANIES 232 15.6.2 RESPONSIVE COMPANIES 232 15.6.3 DYNAMIC COMPANIES 233 15.6.4 STARTING BLOCKS 233 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 234 15.6.5.1 Detailed list of key startups/SMEs, 2025 234 15.6.5.2 Competitive benchmarking of key startups/SMEs, 2025 235 15.7 COMPANY VALUATION & FINANCIAL METRICS 236 15.8 BRAND COMPARISON 237 15.9 COMPETITIVE SCENARIO 238 15.9.1 PRODUCT LAUNCHES & APPROVALS 238 15.9.2 DEALS 240 15.9.3 EXPANSIONS 241   16 COMPANY PROFILES 242 16.1 KEY PLAYERS 242 16.1.1 SIEMENS HEALTHINEERS AG 242 16.1.1.1 Business overview 242 16.1.1.2 Products/Solutions/Services offered 244 16.1.1.3 Recent developments 245 16.1.1.3.1 Product approvals 245 16.1.1.3.2 Deals 246 16.1.1.4 MnM view 247 16.1.1.4.1 Key strengths 247 16.1.1.4.2 Strategic choices 248 16.1.1.4.3 Weaknesses & competitive threats 248 16.1.2 ELEKTA 249 16.1.2.1 Business overview 249 16.1.2.2 Products/Solutions/Services offered 250 16.1.2.3 Recent developments 251 16.1.2.3.1 Product launches & approvals 251 16.1.2.3.2 Deals 252 16.1.2.3.3 Expansions 254 16.1.2.4 MnM view 254 16.1.2.4.1 Key strengths 254 16.1.2.4.2 Strategic choices 254 16.1.2.4.3 Weaknesses & competitive threats 254 16.1.3 ACCURAY INCORPORATED 255 16.1.3.1 Business overview 255 16.1.3.2 Products/Solutions/Services offered 256 16.1.3.3 Recent developments 257 16.1.3.3.1 Product launches & approvals 257 16.1.3.3.2 Deals 258 16.1.3.3.3 Expansions 259 16.1.3.4 MnM view 259 16.1.3.4.1 Key strengths 259 16.1.3.4.2 Strategic choices 259 16.1.3.4.3 Weaknesses & competitive threats 259 16.1.4 IBA WORLDWIDE 260 16.1.4.1 Business overview 260 16.1.4.2 Products/Solutions/Services offered 261 16.1.4.3 Recent developments 262 16.1.4.3.1 Products launches 262 16.1.4.3.2 Deals 263 16.1.4.4 MnM view 264 16.1.4.4.1 Key strengths 264 16.1.4.4.2 Strategic choices 264 16.1.4.4.3 Weaknesses & competitive threats 265 16.1.5 VIEWRAY SYSTEMS, INC. 266 16.1.5.1 Business overview 266 16.1.5.2 Products/Solutions/Services offered 266 16.1.5.3 Recent developments 267 16.1.5.3.1 Product approvals 267 16.1.5.3.2 Deals 267 16.1.6 GT MEDICAL TECHNOLOGIES, INC. 269 16.1.6.1 Business overview 269 16.1.6.2 Products/Solutions/Services offered 269 16.1.7 HITACHI HIGH-TECH CORPORATION 270 16.1.7.1 Business overview 270 16.1.7.2 Products/Solutions/Services offered 272 16.1.7.3 Recent developments 272 16.1.7.3.1 Deals 272 16.1.8 SUMITOMO HEAVY INDUSTRIES, LTD. 273 16.1.8.1 Business overview 273 16.1.8.2 Products/Solutions/Services offered 274 16.1.9 ZEISS GROUP 275 16.1.9.1 Business overview 275 16.1.9.2 Products/solutions/services offered 277 16.1.9.3 Recent developments 277 16.1.9.3.1 Products launches 277 16.1.10 MIM SOFTWARE INC. 278 16.1.10.1 Business overview 278 16.1.10.2 Products/Solutions/Services offered 278 16.1.10.3 Recent developments 279 16.1.10.3.1 Product launches & approvals 279 16.1.10.3.2 Deals 279 16.1.11 PANACEA MEDICAL TECHNOLOGIES PVT. LTD. 280 16.1.11.1 Business overview 280 16.1.11.2 Products/Solutions/Services offered 280 16.1.11.3 Recent developments 281 16.1.11.3.1 Product launches 281 16.1.11.3.2 Deals 281 16.1.12 PROVISION HEALTHCARE 282 16.1.12.1 Business overview 282 16.1.12.2 Products/Solutions/Services offered 282 16.1.13 MEVION MEDICAL SYSTEMS 283 16.1.13.1 Business overview 283 16.1.13.2 Products/Solutions/Services offered 283 16.1.13.3 Recent developments 284 16.1.13.3.1 Product launches & approvals 284 16.1.13.3.2 Deals 284 16.1.14 KONINKLIJKE PHILIPS N.V. 286 16.1.14.1 Business overview 286 16.1.14.2 Products/Solutions/Services offered 287 16.1.14.3 Recent developments 288 16.1.14.3.1 Product launches 288 16.2 OTHER PLAYERS 289 16.2.1 SHINVA MEDICAL INSTRUMENT CO., LTD. 289 16.2.2 BRAINLAB AG 290 16.2.3 RAYSEARCH LABORATORIES 291 16.2.4 INTRAOP MEDICAL, INC. 292 16.2.5 OPTIVUS PROTON THERAPY, INC. 293 16.2.6 BEBIG MEDICAL 294 16.2.7 P-CURE 295 16.2.8 THERAGENICS CORPORATION 296 16.2.9 PROTOM INTERNATIONAL 297 16.2.10 DOSISOFT SA 298 16.2.11 ISOAID, LLC 299 16.2.12 MAGNETTX ONCOLOGY SOLUTIONS LTD. 300 17 RESEARCH METHODOLOGY 301 17.1 RESEARCH DATA 301 17.1.1 SECONDARY DATA 302 17.1.1.1 Objectives of secondary research 302 17.1.1.2 List of secondary sources 303 17.1.2 PRIMARY DATA 303 17.1.2.1 Key data from primary sources 304 17.1.2.2 Key industry insights 305 17.2 MARKET ESTIMATION METHODOLOGY 306 17.2.1 BOTTOM-UP APPROACH 307 17.2.2 REVENUE MAPPING-BASED MARKET ESTIMATION 307 17.2.3 USAGE-BASED MARKET ESTIMATION 309 17.2.4 PRIMARY RESEARCH VALIDATION 310 17.2.5 TOP-DOWN APPROACH 311 17.3 DATA TRIANGULATION AND MARKET BREAKDOWN 312 17.4 MARKET SHARE ASSESSMENT 313 17.5 RESEARCH ASSUMPTIONS 314 17.6 RESEARCH LIMITATIONS 314 17.7 RISK ASSESSMENT 315 17.7.1 RISK ASSESSMENT ANALYSIS 315 18 APPENDIX 316 18.1 DISCUSSION GUIDE 316 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 323 18.3 CUSTOMIZATION OPTIONS 325 18.4 RELATED REPORTS 325 18.5 AUTHOR DETAILS 326
圖表清單 List of Tables & Figures
TABLE 1 RADIOTHERAPY MARKET: INCLUSION/EXCLUSION DETAILS 31 TABLE 2 DIFFERENT TYPES OF EXTERNAL BEAM RADIATION THERAPY (EBRT) TECHNIQUES AND ASSOCIATED ADVANTAGES AND DISADVANTAGES 43 TABLE 3 TREATMENT-RELATED EFFECTS AND TOXICITY CONCERNS 50 TABLE 4 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS 51 TABLE 5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 52 TABLE 6 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 54 TABLE 7 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY SYSTEMS, BY REGION, 2023–2025 61 TABLE 8 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD) 62 TABLE 9 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD) 63 TABLE 10 RADIOTHERAPY MARKET: KEY CONFERENCES & EVENTS, 2026–2027 64 TABLE 11 US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY 69 TABLE 12 TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS 69 TABLE 13 RADIOTHERAPY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2020–2026 76 TABLE 14 KEY CLINICAL TRIALS EVALUATING ARTIFICIAL INTELLIGENCE IN RADIOTHERAPY 78 TABLE 15 KEY AI USE CASES AND MARKET POTENTIAL IN RADIOTHERAPY MARKET 79 TABLE 16 KEY CLINICAL CASE STUDIES OF ARTIFICIAL INTELLIGENCE APPLICATIONS IN RADIOTHERAPY 81 TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 21 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 22 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 87 TABLE 23 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES 87 TABLE 24 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 89 TABLE 25 INDIA: MEDICAL DEVICE CLASSIFICATION UNDER CDSCO 90 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY SYSTEMS 92 TABLE 27 KEY BUYING CRITERIA FOR RADIOTHERAPY SYSTEMS 93 TABLE 28 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS 94 TABLE 29 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 2024–2031 (USD MILLION) 96 TABLE 30 RADIOTHERAPY SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 97 TABLE 31 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION) 98 TABLE 32 RADIOTHERAPY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 100 TABLE 33 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 100 TABLE 34 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 101 TABLE 35 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 102 TABLE 36 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 103 TABLE 37 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 104 TABLE 38 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD & NECK CANCER, BY REGION, 2024–2031 (USD MILLION) 105 TABLE 39 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 106 TABLE 40 OTHER EBRT APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 107 TABLE 41 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 107 TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION) 108 TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION) 109 TABLE 44 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 110 TABLE 45 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 46 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR CERVICAL CANCER, BY REGION, 2024–2031 (USD MILLION) 112 TABLE 47 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PENILE CANCER, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 48 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR OTHER IBRT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 113 TABLE 49 RADIOTHERAPY MARKET, BY PROCEDURE, 2024–2031 (USD MILLION) 115 TABLE 50 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 116 TABLE 51 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION, 2024–2031 (USD MILLION) 116 TABLE 52 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 53 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 118 TABLE 54 PARTICLE THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 55 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 121 TABLE 56 STEREOTACTIC RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 57 OTHER EBRT PROCEDURES MARKET, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 123 TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 60 LDR BRACHYTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 61 HDR BRACHYTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 62 PDR BRACHYTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 63 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 128 TABLE 64 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 129 TABLE 65 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 66 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 67 LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 68 CONVENTIONAL LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 131 TABLE 69 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132 TABLE 70 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 132 TABLE 71 CYBERKNIFE MARKET, BY REGION, 2024–2031 (USD MILLION) 134 TABLE 72 GAMMA KNIFE MARKET, BY REGION, 2024–2031 (USD MILLION) 135 TABLE 73 TOMOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 74 MRI LINACS MARKET, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 75 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 137 TABLE 76 PARTICLE THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 138 TABLE 77 CYCLOTRONS THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 78 SYNCHROTRONS THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 79 SYNCHROCYCLOTRONS THERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 80 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 81 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 143 TABLE 82 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 83 SEEDS MARKET, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 84 AFTERLOADERS MARKET, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 85 IORT SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 86 APPLICATORS MARKET, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 87 RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 149 TABLE 88 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 89 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 90 RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 91 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 92 NORTH AMERICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 155 TABLE 93 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 155 TABLE 94 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 95 NORTH AMERICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 96 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 97 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 156 TABLE 98 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 157 TABLE 99 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 157 TABLE 100 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 158 TABLE 101 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 158 TABLE 102 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 103 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 159 TABLE 104 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 160 TABLE 105 US: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 160 TABLE 106 US: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 107 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 108 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 162 TABLE 109 CANADA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 110 CANADA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 111 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 112 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 113 EUROPE: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 164 TABLE 114 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 165 TABLE 115 EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 116 EUROPE: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 117 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 118 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 166 TABLE 119 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 120 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 121 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 167 TABLE 122 EUROPE: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 123 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 124 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 169 TABLE 125 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 170 TABLE 126 GERMANY: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 127 GERMANY: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 128 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 171 TABLE 129 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 172 TABLE 130 FRANCE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 131 FRANCE: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 132 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 173 TABLE 133 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 174 TABLE 134 UK: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 135 UK: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 136 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 137 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 176 TABLE 138 SPAIN: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 139 SPAIN: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 140 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 177 TABLE 141 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 178 TABLE 142 ITALY: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 143 ITALY: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 144 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 145 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 180 TABLE 146 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 180 TABLE 147 REST OF EUROPE: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 148 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 181 TABLE 149 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 150 ASIA PACIFIC: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 183 TABLE 151 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 183 TABLE 152 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 183 TABLE 153 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 154 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 184 TABLE 155 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 184 TABLE 156 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185 TABLE 157 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 185 TABLE 158 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 159 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 160 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 161 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 187 TABLE 162 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 188 TABLE 163 JAPAN: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 164 JAPAN: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 165 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 189 TABLE 166 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 190 TABLE 167 CHINA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 168 CHINA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 169 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 191 TABLE 170 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 192 TABLE 171 INDIA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 172 INDIA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 173 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 193 TABLE 174 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 194 TABLE 175 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 176 SOUTH KOREA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 177 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 195 TABLE 178 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 196 TABLE 179 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 180 AUSTRALIA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 181 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 197 TABLE 182 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 198 TABLE 183 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 198 TABLE 184 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 185 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 199 TABLE 186 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 187 LATIN AMERICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 200 TABLE 188 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 200 TABLE 189 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 190 LATIN AMERICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 191 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 192 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 201 TABLE 193 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 194 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 195 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 203 TABLE 196 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 197 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 204 TABLE 198 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 205 TABLE 199 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 206 TABLE 200 BRAZIL: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 201 BRAZIL: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 206 TABLE 202 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 207 TABLE 203 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 208 TABLE 204 MEXICO: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 205 MEXICO: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 206 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 207 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209 TABLE 208 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 209 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 210 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 211 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY REGION, 2024–2031 (USD MILLION) 211 TABLE 212 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024–2031 (USD MILLION) 211 TABLE 213 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 212 TABLE 214 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 215 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 212 TABLE 216 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 217 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024–2031 (USD MILLION) 213 TABLE 218 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 213 TABLE 219 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 220 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 221 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 222 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 223 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER, 2024–2031 (USD MILLION) 216 TABLE 224 GCC COUNTRIES: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 217 TABLE 225 GCC COUNTRIES: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 226 GCC COUNTRIES: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 227 GCC COUNTRIES: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 218 TABLE 228 REST OF MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 218 TABLE 229 REST OF MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 230 REST OF MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 231 REST OF MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024–2031 (USD MILLION) 219 TABLE 232 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOTHERAPY MARKET, JANUARY 2022–MAY 2026 220 TABLE 233 RADIOTHERAPY MARKET: DEGREE OF COMPETITION 226 TABLE 234 RADIOTHERAPY MARKET: REGION FOOTPRINT 230 TABLE 235 RADIOTHERAPY MARKET: TECHNOLOGY FOOTPRINT 230 TABLE 236 RADIOTHERAPY MARKET: APPLICATION FOOTPRINT 231 TABLE 237 RADIOTHERAPY MARKET: END-USER FOOTPRINT 232 TABLE 238 RADIOTHERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 234 TABLE 239 RADIOTHERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 235 TABLE 240 RADIOTHERAPY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2026 238 TABLE 241 RADIOTHERAPY MARKET: DEALS, JANUARY 2022–MAY 2026 240 TABLE 242 RADIOTHERAPY MARKET: EXPANSIONS, JANUARY 2022–MAY 2026 241 TABLE 243 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 242 TABLE 244 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED 244 TABLE 245 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2022–MAY 2026 245 TABLE 246 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022−MAY 2026 246 TABLE 247 ELEKTA: COMPANY OVERVIEW 249 TABLE 248 ELEKTA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 250 TABLE 249 ELEKTA: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022−MAY 2026 251 TABLE 250 ELEKTA: DEALS, JANUARY 2022−MAY 2026 252 TABLE 251 ELEKTA: EXPANSIONS, JANUARY 2022−MAY 2026 254 TABLE 252 ACCURAY INCORPORATED: COMPANY OVERVIEW 255 TABLE 253 ACCURAY INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED 256 TABLE 254 ACCURAY INCORPORATED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022−MAY 2026 257 TABLE 255 ACCURAY INCORPORATED: DEALS, JANUARY 2022−MAY 2026 258 TABLE 256 ACCURAY INCORPORATED: EXPANSIONS, JANUARY 2022−MAY 2026 259 TABLE 257 IBA WORLDWIDE: COMPANY OVERVIEW 260 TABLE 258 IBA WORLDWIDE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 261 TABLE 259 IBA WORLDWIDE: PRODUCT LAUNCHES, JANUARY 2022−MAY 2026 262 TABLE 260 IBA WORLDWIDE: DEALS, JANUARY 2022−MAY 2026 263 TABLE 261 VIEWRAY SYSTEMS, INC.: COMPANY OVERVIEW 266 TABLE 262 VIEWRAY SYSTEMS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 266 TABLE 263 VIEWRAY SYSTEMS, INC.: PRODUCT APPROVALS, JANUARY 2022−MAY 2026 267 TABLE 264 VIEWRAY SYSTEMS, INC.: DEALS, JANUARY 2022−MAY 2026 267 TABLE 265 GT MEDICAL TECHNOLOGIES, INC.: COMPANY OVERVIEW 269 TABLE 266 GT MEDICAL TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 269 TABLE 267 HITACHI HIGH-TECH CORPORATION: COMPANY OVERVIEW 270 TABLE 268 HITACHI HIGH-TECH CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 272 TABLE 269 HITACHI HIGH-TECH CORPORATION: DEALS, JANUARY 2022−MAY 2026 272 TABLE 270 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY OVERVIEW 273 TABLE 271 SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCTS/SOLUTIONS/ SERVICES OFFERED 274 TABLE 272 ZEISS GROUP : COMPANY OVERVIEW 275 TABLE 273 ZEISS GROUP: PRODUCTS/SOLUTIONS/SERVICES OFFERED 277 TABLE 274 ZEISS GROUP: PRODUCT LAUNCHES, JANUARY 2022−MAY 2026 277 TABLE 275 MIM SOFTWARE INC.: COMPANY OVERVIEW 278 TABLE 276 MIM SOFTWARE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 278 TABLE 277 MIM SOFTWARE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022−MAY 2026 279 TABLE 278 MIM SOFTWARE INC.: DEALS, JANUARY 2022−MAY 2026 279 TABLE 279 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW 280 TABLE 280 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCTS/SOLUTIONS/ SERVICES OFFERED 280 TABLE 281 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCT LAUNCHES , JANUARY 2022−MAY 2026 281 TABLE 282 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: DEALS, JANUARY 2022−MAY 2026 281 TABLE 283 PROVISION HEALTHCARE: COMPANY OVERVIEW 282 TABLE 284 PROVISION HEALTHCARE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 282 TABLE 285 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW 283 TABLE 286 MEVION MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 283 TABLE 287 MEVION MEDICAL SYSTEMS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022−MAY 2026 284 TABLE 288 MEVION MEDICAL SYSTEMS: DEALS, JANUARY 2022−MAY 2026 284 TABLE 289 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 286 TABLE 290 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 287 TABLE 291 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2022−MAY 2026 288 TABLE 292 SHINVA MEDICAL INSTRUMENT CO., LTD.: COMPANY OVERVIEW 289 TABLE 293 BRAINLAB AG: COMPANY OVERVIEW 290 TABLE 294 RAYSEARCH LABORATORIES: COMPANY OVERVIEW 291 TABLE 295 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW 292 TABLE 296 OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW 293 TABLE 297 BEBIG MEDICAL: COMPANY OVERVIEW 294 TABLE 298 P-CURE: COMPANY OVERVIEW 295 TABLE 299 THERAGENICS CORPORATION: COMPANY OVERVIEW 296 TABLE 300 PROTOM INTERNATIONAL: COMPANY OVERVIEW 297 TABLE 301 DOSISOFT SA: COMPANY OVERVIEW 298 TABLE 302 ISOAID, LLC: COMPANY OVERVIEW 299 TABLE 303 MAGNETTX ONCOLOGY SOLUTIONS LTD.: COMPANY OVERVIEW 300 TABLE 304 RADIOTHERAPY MARKET: RESEARCH ASSUMPTIONS 314 FIGURE 1 RADIOTHERAPY MARKET SEGMENTATION AND REGIONAL SCOPE 30 FIGURE 2 DURATION COVERED 32 FIGURE 3 MARKET SCENARIO 34 FIGURE 4 GLOBAL RADIOTHERAPY MARKET, 2024–2031 34 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET, 2022–2026 35 FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF RADIOTHERAPY MARKET 36 FIGURE 7 HIGH-GROWTH SEGMENTS IN RADIOTHERAPY MARKET, 2026–2031 37 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN RADIOTHERAPY MARKET DURING FORECAST PERIOD 38 FIGURE 9 ADVANCEMENTS IN AI AND ADAPTIVE RADIOTHERAPY ENHANCE TREATMENT PRECISION 39 FIGURE 10 NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD 40 FIGURE 11 EXTERNAL BEAM RADIATION THERAPY SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025 40 FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 41 FIGURE 13 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42 FIGURE 14 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 55 FIGURE 15 RADIOTHERAPY MARKET: VALUE CHAIN ANALYSIS 58 FIGURE 16 RADIOTHERAPY MARKET: ECOSYSTEM ANALYSIS 59 FIGURE 17 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY SYSTEMS, BY REGION, 2023–2025 (USD) 61 FIGURE 18 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 62 FIGURE 19 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 63 FIGURE 20 RADIOTHERAPY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 65 FIGURE 21 RADIOTHERAPY MARKET: INVESTMENT & FUNDING SCENARIO, 2019–2023 65 FIGURE 22 RADIOTHERAPY MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 66 FIGURE 23 VALUE OF INVESTOR DEALS IN RADIOTHERAPY MARKET, BY KEY PLAYER, 2019–2023 66 FIGURE 24 PATENT ANALYSIS FOR RADIOTHERAPY MARKET, JANUARY 2016–DECEMBER 2025 75 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY SYSTEMS 92 FIGURE 26 KEY BUYING CRITERIA FOR RADIOTHERAPY SYSTEMS 93 FIGURE 27 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT 154 FIGURE 28 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT 182 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET, 2021−2025 225 FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET, 2025 226 FIGURE 31 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 228 FIGURE 32 RADIOTHERAPY MARKET: COMPANY FOOTPRINT 229 FIGURE 33 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 233 FIGURE 34 EV/EBITDA OF KEY VENDORS 236 FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 236 FIGURE 36 RADIOTHERAPY MARKET: BRAND COMPARATIVE ANALYSIS 237 FIGURE 37 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 243 FIGURE 38 ELEKTA: COMPANY SNAPSHOT 250 FIGURE 39 ACCURAY INCORPORATED: COMPANY SNAPSHOT 256 FIGURE 40 IBA WORLDWIDE: COMPANY SNAPSHOT 261 FIGURE 41 HITACHI HIGH-TECH CORPORATION: COMPANY SNAPSHOT 271 FIGURE 42 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT 274 FIGURE 43 ZEISS GROUP: COMPANY SNAPSHOT 276 FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 287 FIGURE 45 RESEARCH DESIGN 301 FIGURE 46 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 304 FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 306 FIGURE 48 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 307 FIGURE 49 RADIOTHERAPY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 308 FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025) 309 FIGURE 51 RADIOTHERAPY MARKET: MARKET SIZE ESTIMATION METHODOLOGY 310 FIGURE 52 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 311 FIGURE 53 DATA TRIANGULATION METHODOLOGY 313

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們